These authors demonstrated in this rat MI model that GYY4137 administration over a 7-day period attenuated early adverse cardiac remodeling, and concluded that this may have been moderated by activation of the cardiac hormone ANP, with increased Nppa (but not Nppb) expression by 2 days post-MI [3]. Here, NPPA is linked to myocardial infarction.